Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Moderate Buy” by Analysts
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among […]
